A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
Braz. j. infect. dis
;
15(5): 498-500, Sept.-Oct. 2011.
Artículo
en Inglés
| LILACS
| ID: lil-612714
ABSTRACT
Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIVpositive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replication.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Sulfonamidas
/
Infecciones por VIH
/
Inhibidores de la Proteasa del VIH
/
Ritonavir
Límite:
Adulto
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Braz. j. infect. dis
Asunto de la revista:
Enfermedades Transmisibles
Año:
2011
Tipo del documento:
Artículo
País de afiliación:
Botswana
/
Italia
Institución/País de afiliación:
G.B. Rossi Hospital/IT
/
University of Botswana/BW
/
University of Torino/IT
Similares
MEDLINE
...
LILACS
LIS